Atazanavir

Contraindicated

Atazanavir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Atazanavir Simvastatin Flolipid Explained An increased risk of simvastatin toxicity, including an increased risk of myopathy or rhabdomyolysis Details Atazanavir Alfuzosin UroXatral Increased alfuzosin exposure and an increased risk of QT interval prolongation Details Atazanavir Dihydroergotamine Injection DHE-45® Injection An increased risk of peripheral vasospasm and ischemia of the extremities and other tissues Details Atazanavir Dihydroergotamine Nasal Spray Migranal An increased risk of peripheral vasospasm and ischemia of the extremities and other tissues Details Atazanavir Encorafenib Braftovi Reduced atazanavir exposure, reduced efficacy of atazanavir, increased encorafenib exposure and an increased risk of QT interval p... Details Atazanavir Irinotecan Camptosar Increased irinotecan and its active metabolite, SN-38 exposure Details Atazanavir Irinotecan Injection Camptosar Increased irinotecan and its active metabolite, SN-38 exposure Details Atazanavir Irinotecan Lipid Complex Injection Onivyde® Increased irinotecan and its active metabolite, SN-38 exposure Details Atazanavir Ketoconazole Topical Extina® Foam Increased atazanavir exposure, increased ketoconazole exposure and an increased risk for QT interval prolongation Details Atazanavir Lefamulin Xenleta Increased lefamulin and atazanavir exposure and an increased risk of QT interval prolongation Details Atazanavir Lovastatin Altocor® Increased risk of lovastatin toxicity, including an increased risk of myopathy or rhabdomyolysis Details Atazanavir Lurasidone Latuda Increased lurasidone exposure Details Atazanavir Maraviroc Selzentry Increased exposure of maraviroc Details Atazanavir Methylergonovine Methergine An increased risk of peripheral vasospasm and ischemia of the extremities and other tissues Details Atazanavir Midazolam Nasal Spray Nayzilam Increased midazolam exposure Details Atazanavir Midazolam Injection Nayzilam Increased midazolam exposure Details Atazanavir Nevirapine Viramune Reduced atazanavir exposure, an increased risk of virologic failure, increased nevirapine exposure and an increased risk of nevira... Details

Major

Atazanavir Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Atazanavir Abametapir Explained Increased exposure of CYP3A4 substrate Details Atazanavir Omeprazole Gastrobim Explained Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Atazanavir Amitriptyline Elavil Explained Increased TCA exposure and an increased risk of QT interval prolongation Details Atazanavir Sertraline Explained An increased risk of QT interval prolongation Details Atazanavir Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure, an increased risk of buprenorphine-related advers... Details Atazanavir Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Atazanavir Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Atazanavir Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Atazanavir Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Atazanavir Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Atazanavir Arsenic Trioxide Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Atazanavir Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Atazanavir Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Atazanavir Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Atazanavir Atogepant Qulipta Increased atogepant exposure Details Atazanavir Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Atazanavir Azithromycin AzaSite An increased risk of QT interval prolongation Details Atazanavir Betrixaban Bevyxxa® Increased betrixaban exposure and an increased risk of bleeding Details Atazanavir Atorvastatin Atorvaliq Increased risk of atorvastatin toxicity, including an increased risk of myopathy or rhabdomyolysis Details Atazanavir Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Atazanavir Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details